Cobenfy

What Cobenfy does

Cobenfy is a prescription pharmaceutical brand marketing COBENFY (xanomeline and trospium chloride), an FDA-approved oral fixed-dose combination medication for the treatment of schizophrenia in adults. COBENFY is the first and only FDA-approved schizophrenia medicine that works by activating muscarinic acetylcholine receptors in the brain, combining a muscarinic agonist (xanomeline) with a muscarinic antagonist (trospium chloride) intended to limit peripheral side effects. The product is available in three capsule strengths (50mg/20mg, 100mg/20mg, and 125mg/30mg) administered twice daily, allowing for gradual titration. COBENFY is a registered trademark of Karuna Therapeutics, Inc., which was acquired by Bristol Myers Squibb, and the product is currently marketed in the United States only.

The company operates a direct-to-consumer pharmaceutical model targeting the approximately 2.8 million U.S. adults living with schizophrenia. COBENFY generates revenue through prescription sales distributed via retail and mail-order pharmacies at a WAC of $1,887 per 30-day supply, with a co-pay assistance program potentially bringing eligible commercially insured patients to $0 out-of-pocket and parallel programs for Medicaid and Medicare Extra Help beneficiaries. The revenue model is inherently recurring given the chronic nature of schizophrenia maintenance therapy.

The go-to-market combines a patient-facing DTC website (cobenfy.com), a separate HCP-focused website (cobenfyhcp.com), real-patient testimonials, downloadable patient and care-partner resources, an email newsletter, and the COBENFY Cares patient support program offering 24/7 individualized support, insurance navigation, and co-pay assistance. Distribution is executed through U.S. retail and mail-order pharmacies with free physician sample wallets for initial titration, and the brand maintains referral relationships with community mental health organizations including NAMI, Mental Health America, and the Schizophrenia & Psychosis Action Alliance.

Name

Cobenfy

Legal name

Karuna Therapeutics, Inc.

Website

https://cobenfy.com

Company type

Private

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

COBENFY is an FDA-approved oral fixed-dose combination of xanomeline and trospium chloride marketed by Bristol Myers Squibb for the treatment of schizophrenia in adults, sold via U.S. retail and mail-order pharmacies with a dedicated patient support program.

Ownership category

akta.pro rank

Product category

Antipsychotic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Schizophrenia treatment
• Muscarinic receptor therapy
• Antipsychotic medication
• Combination drug therapy
• Patient support program

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

1. Prescription pharmaceutical sales: COBENFY generates revenue through prescription sales dispensed at retail and mail-order pharmacies. Patients with insurance may pay less than WAC price through co-pay assistance programs. The drug is available as a 30-day supply of capsules taken twice daily.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Cobenfy markets COBENFY, an FDA-approved oral fixed-dose combination of xanomeline and trospium chloride indicated for the treatment of schizophrenia in adults. It is sold as a 30-day supply of capsules taken twice daily across three dosage strengths, distributed exclusively by prescription at retail and mail-order pharmacies, and accompanied by the COBENFY Cares patient support program and co-pay savings offerings.

Product overview

COBENFY is a single FDA-approved prescription medication (not a software platform) consisting of a fixed-dose combination of xanomeline and trospium chloride. The product is available in three dosage strengths (50mg/20mg, 100mg/20mg, and 125mg/30mg capsules) administered twice daily. Patient support is provided through the COBENFY Cares program, which offers 1-on-1 coaching, insurance navigation, and co-pay assistance. Educational resources include downloadable guides such as the Discussion Guide, Patient Brochure, Getting Started Brochure, Care Partner Brochure, Symptom Tracker, and Care Partner Worksheet/Checklist.

Differentiator

Problem solved

Functional benefit

Brands

• COBENFY Cares: A patient support program offering free 1-on-1 support from COBENFY Cares Champions, insurance coverage assistance, and co-pay savings for patients prescribed COBENFY.

Products and services

• COBENFY (xanomeline and trospium chloride) FDA-approved oral fixed-dose combination prescription medication for the treatment of schizophrenia in adults; the first and only schizophrenia medicine thought to work by activating muscarinic acetylcholine receptors in the brain. Taken twice daily as a 30-day supply of capsules.

Quantifiable outcome

• Significant relief of schizophrenia symptoms overall vs placebo (sugar pill) in two 5-week clinical studies
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Bristol Myers SquibbcoreOthersBristol Myers Squibb acquired COBENFY through its acquisition of Karuna Therapeutics, Inc. COBENFY, Cobenfy Cares, and the Cobenfy logo are trademarks of Karuna Therapeutics, Inc., a Bristol Myers Squibb company. BMS manufactures and commercializes COBENFY for the treatment of schizophrenia in adults.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sumitomo Pharma America: Markets Latuda (lurasidone), a branded atypical antipsychotic approved for schizophrenia in adults. Direct prescription-pharma competitor with similar DTC+HCP marketing approach in U.S. psychiatry.
• Alkermes: Markets Lybalvi (olanzapine/samidorphan), a branded oral antipsychotic for adults with schizophrenia. Comparable single-indication, specialty-pharma commercial profile and prescriber base.
• Intra-Cellular Therapies: Markets Caplyta (lumateperone), an FDA-approved branded therapy for schizophrenia in adults. Direct competitor in the same branded CNS/schizophrenia space with similar specialty-pharma commercial model.
• Vanda Pharmaceuticals: Markets Fanapt (iloperidone), a branded oral antipsychotic for schizophrenia. Comparable small-cap specialty pharma focused on a single CNS antipsychotic asset.

Emerging players

• AbbVie (Cerevel Therapeutics): Acquired Cerevel Therapeutics to build a CNS pipeline including muscarinic-based schizophrenia candidates. Comparable muscarinic-mechanism competitor in development that could pressure COBENFY's first-mover advantage.
• Neumora Therapeutics: Clinical-stage neuroscience company with a schizophrenia pipeline targeting novel CNS mechanisms. Emerging competitor with overlapping scientific approach and prescriber target audience.

Broad incumbents

• Eli Lilly: Historical schizophrenia incumbent via Zyprexa (olanzapine) and ongoing CNS portfolio. Broad big-pharma peer with established psychiatry commercial channels that compete for the same physician audience.
• Otsuka Pharmaceutical: Sells Rexulti (brexpiprazole) and Abilify Maintena (aripiprazole) for schizophrenia and related CNS indications. Established large-pharma incumbent with broad psychiatry portfolio overlapping COBENFY's target prescribers.
• Janssen Pharmaceuticals (Johnson & Johnson): Long-established player in schizophrenia via Risperdal Consta, Invega Sustenna/Invega Hafyera (paliperidone long-acting injectables). Broad incumbent with overlapping prescriber base and deeper psychiatry infrastructure.
• Teva Pharmaceutical Industries: Major generic and branded antipsychotic manufacturer, including generic clozapine. Sets the pricing floor COBENFY must overcome and competes for the same formulary slots.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/COBENFY

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cobenfy